# Denotes UMass undergraduate
Rodberg EM, den Hartog CR, Anderson RI, Becker HC, Moorman DE, Vazey EM. Stress facilitates the development of cognitive dysfunction after chronic ethanol exposure. Alcoholism, clinical and experimental research, 2017 In press.
Kelberman MA#, Vazey EM. New Pharmacological approaches to treateing non-motor symptoms of Parkinson’s disease. Current Pharmacology Reports, 2016 Dec;2(6):253-261.
Prior to UMass
den Hartog CR, Zamudio-Bulcock P, Nimitvilai S, Gilstrap M, Fedarovich H, Motts A, Woodward JJ. Inactivation of the lateral orbitofrontal cortex increases drinking in ethanol-dependent but not non-dependent mice. Neuropharmacology, 2016 Aug;107:451-9.
Fortress AM, Hamlett ED, Vazey EM, Aston-Jones G, Cass WA, Boger HA, Granholm AC. Designer receptors enhance memory in a mouse model of down syndrome. Journal of Neuroscience, 2015 Jan, 28; 35(4): 1343-53.
Vazey EM, Aston-Jones G. Designer receptors: therapeutic adjuncts to cell replacement therapy in Parkinson’s disease. Journal of Clinical Investigation, 2014, Jul; 124(7): 2858-60.
Mahler SV, Vazey EM, Beckley JT, Keistle, CR, McGlinchey EM, Kaufling J, Wilson SP, Deisseroth K, Woodward JJ, Aston-Jones G. Designer receptors show role for ventral pallidum input to ventral tegmental area in cocaine seeking.Nature Neuroscience, 2014, Apr; 17(4): 577-85.
Vazey EM, Aston-Jones G. Designer receptor manipulations reveal a role of the locus coeruleus noradrenergic system in isoflurane general anesthesia. Proceedings of the National Academy of Sciences U S A, 2014, Mar 11;111(10): 3859-64.
Pava MJ, den Hartog CR, Blanco-Centurion C, Shiromani PJ, Woodward JJ. Endocannabinoid modulation of cortical up-states and NREM sleep. PLoS ONE, 2014 Feb; 9(2).
den Hartog CR, Beckley JT, Smothers TC, Lench DH, Holseberg ZL, Fedarovich H, Woodward JJ. Alterations in ethanol-induced behaviors and consumption in knock-in mice expressing ethanol-resistant NMDA receptors. PLoS ONE, 2013 Nov; 8(11).
Vazey EM, Aston-Jones, G. New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson’s disease. Brain Research, 2013, May 20; 1511: 153-63.
Maucksch C, Vazey EM, Gordon RJ, Connor B. Stem cell-based therapy for Huntington’s disease. Journal of Cellular Biochemistry, 2013, Apr; 114(4): 754-63.
Vazey EM, Aston-Jones G. The emerging role of norepinephrine in cognitive dysfunctions of Parkinson’s disease.Frontiers in Behavioral Neuroscience, 2012, Jul 25; 6: 48.
Reissner KJ, Sartor GC, Vazey EM, Dunn TE, Aston-Jones G, Kalivas P. Use of vivo-morpholinos for control of protein expression in the adult rat brain. Journal of Neuroscience Methods, 2012 Jan 30; 203(2): 354-60.
Vazey EM, Connor B. Differential fate and functional outcome of lithium chloride primed adult neural progenitor cell transplants in a rat model of Huntington disease. Stem Cell Research and Therapy, 2010, Dec 22; 1(5): 41.
Vazey EM, Dottori M, Jamshidi P, Tomas D, Pera MF, Horne M, Connor B. Comparison of transplant efficiency between spontaneously derived and noggin-primed human embryonic stem cell neural precursors in the quinolinic acid rat model of Huntington’s disease. Cell Transplantation, 2010; 19(8): 1055-62.
Vazey EM, Connor B. In vitro priming to direct neuronal fate in adult neural progenitor cells. Experimental Neurology, 2009, Apr; 216(2): 520-4.
Gordon RJ, Tattersfield AS, Vazey EM, Kells AP, McGregor AL, Hughes SM, Connor B. Temporal profile of subventricular zone progenitor cell migration following quinolinic acid-induced striatal cell loss. Neuroscience, 2007, Jun 8; 146(4): 1704-18.
Vazey EM, Chen K, Hughes SM, Connor B. Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington’s disease. Experimental Neurology, 2006, Jun;199(2): 384-96.